COPD activates bitter taste receptors, the target of asthma treatment

Published Date: 17 Mar 2023

Germany: Activation of bitter taste receptors opens lung pathways, making them potential targets for the treatment of chronic lung diseases...

Read Full News

Latest News

Closing the COVID-19 Prevention Gap This Flu Season, With Juanita Mora, MD

Closing the COVID-19 Prevention Gap This Flu Season, With Juanita Mora, MD

The HCPFive: Top News for Healthcare Providers from the Week of 11/1

The HCPFive: Top News for Healthcare Providers from the Week of 11/1

Q&A: Discussing 2027 GOLD Report Updates in COPD, With David Singh, MD

Q&A: Discussing 2027 GOLD Report Updates in COPD, With David Singh, MD

AI Not Yet Ready for COPD Prognosis, With Jean Bourbeau, MD Jean Bourbeau, MD

AI models have not outperformed existing clinical scores for COPD prognosis, but home monitoring may help track disease activity, Bourbeau said.

Breath-Hold Does Not Improve Robotic Bronchoscopy Yield: STABLE Trial Roshen Mathew, MD, DAABIP

Among 117 patients, breath-hold ventilation did not improve strict diagnostic yield vs conventional (86.8% vs 92.2%) in robotic bronchoscopy.

AD109 Cuts AHI by 59.6% in Postmenopausal Women With OSA Reena Mehra, MD

In a post hoc analysis of 2 phase 3 trials, AD109 reduced hypoxic burden by 69.8% vs 20.0% with placebo in postmenopausal women with OSA.

Todays Updates

Episode 179: Cognitive Changes in Multiple Sclerosis: Rethinking Processing Speed and Memory James F. Sumowski, PhD, Isabella Ciccone, MPH

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with James F. Sumowski, PhD. [LISTEN TIME: 21 minutes]

Early ACHIEVE Findings Move Z-Basivarsen Toward Phase 3 in Myotonic Dystrophy Type 1 Marco Meglio, Laurie Gutmann, MD

Laurie Gutmann, MD, chair of the Department of Neurology at Indiana University School of Medicine, discusses one-year pooled ACHIEVE data for z-basivarsen (DYNE-101), an investigational antisense oligonucleotide, in myotonic dystrophy type 1 (DM1).

Treating Depression in CKD After CONCORD, With Susan Hedayati, MD, MHSc Susan Hedayati, MD, MHSc

Hedayati recommends shared decision making and a 4 to 6 week treatment trial, stopping therapy when patients don’t respond.

Imlifidase Opens a Transplant Window, With Oriol Bestard, MD, PhD Oriol Bestard, MD, PhD

PAES data from ASN Kidney Week 2026 show graft, patient, and kidney function outcomes at 1 year in crossmatch-positive transplants.

ZEUS: Ziltivekimab Fails to Reduce Cardiovascular Events in ASCVD and CKD

ZEUS: Ziltivekimab Fails to Reduce Cardiovascular Events in ASCVD and CKD

ABCs in Dermatology: Rethinking Corticosteroid Stewardship in Chronic Hand Eczema

ABCs in Dermatology: Rethinking Corticosteroid Stewardship in Chronic Hand Eczema

Todays Updates

Episode 179: Cognitive Changes in Multiple Sclerosis: Rethinking Processing Speed and Memory James F. Sumowski, PhD, Isabella Ciccone, MPH

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with James F. Sumowski, PhD. [LISTEN TIME: 21 minutes]

Early ACHIEVE Findings Move Z-Basivarsen Toward Phase 3 in Myotonic Dystrophy Type 1 Marco Meglio, Laurie Gutmann, MD

Laurie Gutmann, MD, chair of the Department of Neurology at Indiana University School of Medicine, discusses one-year pooled ACHIEVE data for z-basivarsen (DYNE-101), an investigational antisense oligonucleotide, in myotonic dystrophy type 1 (DM1).

Treating Depression in CKD After CONCORD, With Susan Hedayati, MD, MHSc Susan Hedayati, MD, MHSc

Hedayati recommends shared decision making and a 4 to 6 week treatment trial, stopping therapy when patients don’t respond.

Imlifidase Opens a Transplant Window, With Oriol Bestard, MD, PhD Oriol Bestard, MD, PhD

PAES data from ASN Kidney Week 2026 show graft, patient, and kidney function outcomes at 1 year in crossmatch-positive transplants.

ZEUS: Ziltivekimab Fails to Reduce Cardiovascular Events in ASCVD and CKD

ZEUS: Ziltivekimab Fails to Reduce Cardiovascular Events in ASCVD and CKD

ABCs in Dermatology: Rethinking Corticosteroid Stewardship in Chronic Hand Eczema

ABCs in Dermatology: Rethinking Corticosteroid Stewardship in Chronic Hand Eczema

Latest News

Closing the COVID-19 Prevention Gap This Flu Season, With Juanita Mora, MD

The HCPFive: Top News for Healthcare Providers from the Week of 11/1

Q&A: Discussing 2027 GOLD Report Updates in COPD, With David Singh, MD

AI models have not outperformed existing clinical scores for COPD prognosis, but home monitoring may help track disease activity, Bourbeau said.

Among 117 patients, breath-hold ventilation did not improve strict diagnostic yield vs conventional (86.8% vs 92.2%) in robotic bronchoscopy.

In a post hoc analysis of 2 phase 3 trials, AD109 reduced hypoxic burden by 69.8% vs 20.0% with placebo in postmenopausal women with OSA.

News All Time

The HCPFive: Top News for Healthcare Providers from the Week of 10/25

The HCPFive: Top News for Healthcare Providers from the Week of 10/25

Inhaled Treprostinil Reduces Recurrent IPF Events, With Steven Nathan, MD Steven D. Nathan, MD, FCCP

A TETON-2 post hoc analysis at CHEST 2026 found 126 progression events with inhaled treprostinil vs 161 with placebo across 52 weeks.

AI Could Help Find Undiagnosed COPD on Lung Cancer Screening CT Jean Bourbeau, MD

Jean Bourbeau, MD, says AI analysis of CT scans is not ready for routine use but could reshape early COPD diagnosis as GOLD expands its AI guidance.

Voceryq Gains FDA Accelerated Approval for Recurrent Respiratory Papillomatosis

Voceryq Gains FDA Accelerated Approval for Recurrent Respiratory Papillomatosis

STABLE Trial: Breath-Hold Does Not Improve Robotic Bronchoscopy Yield Roshen Mathew, MD, DAABIP

Roshen Mathew, MD, DAABIP, discusses STABLE, in which diagnostic yield was 86.8% with breath-hold vs 92.2% with conventional ventilation.

Depemokimab Year 1 Remission Linked to Better Year 2 Asthma Outcomes Michael Wechsler, MD, MSc

Michael Wechsler, MD, reports 59% of patients in clinical remission with twice-yearly depemokimab at year 1 maintained it at year 2 in SWIFT/AGILE.

Experts Discuss PAH Treatment Selection and Access

Experts Discuss PAH Treatment Selection and Access

HCPLive Five at CHEST 2026

HCPLive Five at CHEST 2026

Tozorakimab Improves Daily Respiratory Symptoms in COPD: OBERON, TITANIA Frank C. Sciurba, MD

Frank Sciurba, MD, reports tozorakimab improved E-RS:COPD scores vs placebo at week 52 in OBERON and TITANIA, including breathlessness and chest symptoms.

Earlier PH Screening in ILD: PHINDER Data, With Parth Rali, MD

Earlier PH Screening in ILD: PHINDER Data, With Parth Rali, MD

Weighing Bleeding Risk in Pulmonary Embolism, With Samantha Pettigrew, MD Samantha Pettigrew, MD

At CHEST 2026, Pettigrew reviewed STRATIFY and STORM-PE data, citing bleeding risk with low-dose alteplase and 90-day walk gains with thrombectomy.

AI and Emerging Technologies in COPD Care, With Jean Bourbeau, MD Jean Bourbeau, MD

At CHEST 2026, Jean Bourbeau, MD, said AI may support COPD diagnosis, remote monitoring, and posthospital care, though most tools still need validation.

Tozorakimab Sustains COPD Exacerbation Benefit to 2 Years: Henrik Watz, MD Henrik Watz, MD, PhD

Henrik Watz, MD, discusses 104-week OBERON, TITANIA, and PROSPERO data on tozorakimab in COPD presented at CHEST 2026.

Frespaciguat Misses 6MWD End Point in PH-COPD: Gabor Kovacs, MD, PhD Gabor Kovacs, MD, PhD

Gabor Kovacs, MD, PhD, discusses phase 2a INSIGNIA PH-COPD results for inhaled frespaciguat presented at CHEST 2026.

TPIP Tolerable Over 2 Years in PH-ILD, With Colin Church, MBBS, PhD

TPIP Tolerable Over 2 Years in PH-ILD, With Colin Church, MBBS, PhD

Ralinepag's Benefit Spans Broad PAH Population, With Jean Elwing, MD

Ralinepag's Benefit Spans Broad PAH Population, With Jean Elwing, MD

Recommended News For You

More evidence links physical activity with improved cancer survival

New Standard of Care in High-Risk Acute Promyelocytic Leukemia?

Tumor infiltration of major blood vessels, not metastasis, may be primary cause of cancer death

Multicomponent Test Tops PSA for Clinically Significant Prostate Cancers

Genomic Newborn Screening Could Identify Childhood Cancer Predisposition

In KRAS-mutated non-small cell lung cancer, glecirasib exhibits promising efficacy.

Aspirin Fails to Boost Survival in Colorectal Cancer Trial

Recommended Articles For You

Managing Treatment Transitions During Cancer Care 

Harnessing Artificial Intelligence in Oncology: Innovations in Diagnosis, Treatment, and Patient Care 

Iron Regulation Across Reproductive Life Stages 

Engineered Immune Cells for Brain Tumors: Mechanisms, Clinical Impact, and Future Directions 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Researchers discover that children who survive cancer have socioeconomic challenges.

2.

When in Breast Cancer Treatment Are CDK4/6 Inhibitors Best?

3.

New guidelines for radiation therapy for HPV-associated head and neck cancer

4.

Pelvic RT Tied to Longer Survival in Cervical Cancer

5.

Adding Isatuximab to Standard Backbone Prolongs PFS in Myeloma

1.

Unlocking the Potential of Red Bone Marrow in the Formation of Blood Cells

2.

Uncovering the Mysteries of the RDW Blood Test

3.

A Visual Journey Through Penile Cancer: Examining the Impact of Photos

4.

Modern Approaches to Detecting Residual Disease: Clinical Utility and Future Trends

5.

Immune Niches Supporting Tumor Persistence

1.

International Conference on Innovations in Critical Care for Oncology and Cardiology

2.

International Conference on Oncology, Cardiology and Critical Care Policy

3.

International Conference on Oncology, Cancer Prevention and Public Health

4.

International Conference on Cancer Nursing and Rehabilitation Strategies

5.

International Conference on Best Practices in Oncology, Cardiology and Critical Care

1.

How Advances in Cancer Research Are Improving Treatment Options

2.

Immunotherapy: A New Era in Cancer Treatment

3.

Tumor-Associated Fibroblast Metabolites as Biomarkers of Stromal Activity

4.

Early Warning Signs of Cancer

5.

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part II

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot